CollimateHealth raises €6M seed to bring microbeam radiation therapy to cancer treatment
**What's the deal?** Munich-based CollimateHealth has closed a $6M seed round to develop microbeam radiation therapy — a cancer treatment that uses hair-thin X-ray beams to target tumours while sparing healthy tissue. The oversubscribed round was backed by VP Venture PartnersDealroom has a profile for this one. Try Dealroom →, Positron, XISTA Science VenturesDealroom has a profile for this one. Try Dealroom →, High-Tech Gründerfonds (HTGF), and caesarDealroom has a profile for this one. Try Dealroom →.
The startup, spun out of nearly a decade of research at the Technical University of Munich (TUM), aims to treat its first patients by the end of 2028. It was co-founded in 2025 by Stefan Bartzsch, chief scientific officer, and Johanna Winter, chief technology officer — both long-time TUM researchers.
**Why now?** Traditional radiation therapy hasn't changed much in 50 years. It uses wide beams that kill cancer cells but also damage surrounding healthy tissue. CollimateHealth's approach replaces those beams with arrays of X-rays only tens of micrometres wide — roughly the width of a human hair.
At that scale, treated tumours undergo a form of cell death that activates the immune system, an effect that could extend beyond the irradiated area. The narrow channels also help drugs penetrate tumours more effectively, potentially boosting chemotherapy and immunotherapy.
The global radiation therapy market is worth about €13B and could nearly double by 2034, drawing investors toward novel approaches.
**What could go wrong?** The core engineering challenge is daunting. Producing microbeams at clinical doses typically requires a third-generation synchrotron — a particle accelerator the size of a football stadium. Only a handful exist worldwide for medical research.
CollimateHealth says it has shrunk the necessary beamline to under 10 square metres. "Shrinking the medical beamline of a synchrotron into a system with a footprint of less than 10 square metres is a genuine deep-tech moonshot," chief executive Hans Maria Heÿn said.
There is no large-scale clinical data yet for microbeam therapy, and the regulatory pathway remains unclear. The closest comparable innovation, FLASH therapy, reduces tissue damage through higher dose rates rather than beam shape — but it too lacks extensive clinical validation.
**The signal:** CollimateHealth sits at the intersection of two strong currents in European venture: deep-tech hardware bets and cancer immunotherapy. HTGF, which has backed more than 800 startups since 2005, is one of Europe's most active deep-tech seed investors. Munich continues to strengthen as a hub for TUM spinouts attracting serious capital.
The company's academic partnerships — spanning TUM University Hospital, Helmholtz Institute Mainz, Forschungszentrum Jülich, and The Royal Marsden Hospital in London — signal that institutional research is increasingly willing to back commercialisation of frontier radiation science. If the technology works at scale, it could shift cancer treatment away from blunt-force radiation toward precision tools that recruit the body's own immune response.
Read more: Tech Funding News
